Financing channel feed – Endpoints News

Financing channel feed

James Boylan snags $300M to hunt for biotech deals after leaving SVB

4 years ago

University of Oxford spinoff nets a nine-figure Series B, but it won't beeline toward the clinic

4 years ago

Despite bruising market, two biotechs price their IPOs while another launches its Nasdaq bid

4 years ago

As its slide stretches into a second year, Zymeworks faces takeover bid

4 years ago

Arie and Dan Belldegrun are building biotech campuses around the globe — with a newly raised $3B fund to keep the dirt flying

4 years ago

Syncona-backed biotech launches in bid to shield heart cells from heart attacks

4 years ago

Caladrius’ 16-year rocky history bends again in Cend merger; After Cellectis, China JV pacts, Cytovia inks SPAC deal

4 years ago

Pfizer nabs discounted stake in Zentalis after AACR22 data left the biotech bruised

4 years ago

Irv Weissman's lab spins out another biotech, with help of Forty Seven co-founders, to target new 'don't eat me' signal

4 years ago

Pfizer and Valneva's Lyme disease bet rolls on to PhIII as more financing flows their way

4 years ago

Deerfield-backed biotech emerges from stealth with gene therapy delivery platforms from Harvard and MIT

4 years ago

Serving as a 'gateway,' Cambridge venture investor closes $300M second fund

4 years ago

Microcap biotech seeks a merger or new investment after PhIII flop — shares soar

4 years ago

Following BeiGene, Zai Lab changes auditors amidst SEC threat of delisting

4 years ago

Reify Health thinks clinical trials can be representative by 2030 — and it’s secured the capital to help partners put in the work

4 years ago

Synthetic biology biotech nets three-hit combo in new financing, Bristol Myers deal and first CSO

4 years ago

Welcome to 'tissue therapeutics’: Dave Lennon’s $110M new venture will implant ‘happy cells’ that ‘survive and thrive’

4 years ago

Flagship-founded Tessera fuels up with $300M 'to go on a really big adventure' in gene editing

4 years ago

Riding on wave of clinical trial reforms, machine learning startup bags $50M to create 'digital twins'

4 years ago

On heels of psych drug approval, BioXcel dives head first into oncology R&D with new cash infusion

4 years ago

'Timing couldn't be better': An ex-generics maker goes SPAC route with blank check intended for sports market

4 years ago

OrbiMed-backed biotech looks to challenge Vertex in cystic fibrosis by 'drugging the undruggable'

4 years ago

A medtech company's SPAC merger falls flat, missing on nine-figure valuation

4 years ago

Foresite's Jim Tananbaum yanks $250M SPAC, as an RA-backed Oxford spinout braves the choppy IPO waters

4 years ago

First page Previous page 55 56 575859 60 61 Next page Last page